Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Three stocks that have not only been around for a century but have also been paying dividends for that long are Coca-Cola ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

Eli Lilly's tirzepatide cut the risk of developing type 2 diabetes for people with pre-diabetes by 94%, according to new ...

Eli Lilly's Phase 3 study shows tirzepatide significantly cuts type 2 diabetes risk and supports 22.9% average weight loss in adults over three years.

Eli Lilly (LLY) and Company announced detailed results from the Phase 3 SURMOUNT-1 three-year study, the longest completed study to date of ...

A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

The detailed results were published in The New England Journal of Medicine and were presented at ObesityWeek 2024.

The U.S. had 42M. The Lancet report also noted that obesity, a key risk factor for diabetes, has also increased in most countries in the past few decades, particularly in low-income and middle-income ...

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to ...